Guest Editor

Oncogene 25: 1593; doi:10.1038/sj.onc.1209369

Abstract | Full Text | PDF

Using high-throughput SNP technologies to study cancer

L J Engle, C L Simpson and J E Landers

Oncogene 25: 1594-1601; doi:10.1038/sj.onc.1209368

Abstract | Full Text | PDF

Polymorphisms in the p53 pathway

E C Pietsch, O Humbey and M E Murphy

Oncogene 25: 1602-1611; doi:10.1038/sj.onc.1209367

Abstract | Full Text | PDF

Mouse models of XRCC1 DNA repair polymorphisms and cancer

W C Ladiges

Oncogene 25: 1612-1619; doi:10.1038/sj.onc.1209370

Abstract | Full Text | PDF

Cyclin D1: polymorphism, aberrant splicing and cancer risk

K E Knudsen, J Alan Diehl, C A Haiman and E S Knudsen

Oncogene 25: 1620-1628; doi:10.1038/sj.onc.1209371

Abstract | Full Text | PDF

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions

L Wang and R Weinshilboum

Oncogene 25: 1629-1638; doi:10.1038/sj.onc.1209372

Abstract | Full Text | PDF

Glutathione S-transferase polymorphisms: cancer incidence and therapy

C C McIlwain, D M Townsend and K D Tew

Oncogene 25: 1639-1648; doi:10.1038/sj.onc.1209373

Abstract | Full Text | PDF

N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk

D W Hein

Oncogene 25: 1649-1658; doi:10.1038/sj.onc.1209374

Abstract | Full Text | PDF

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer

S Nagar and R P Remmel

Oncogene 25: 1659-1672; doi:10.1038/sj.onc.1209375

Abstract | Full Text | PDF | Supplementary information

Pharmacogenetics of human cytosolic sulfotransferases

S Nowell and C N Falany

Oncogene 25: 1673-1678; doi:10.1038/sj.onc.1209376

Abstract | Full Text | PDF

Cytochrome P450 pharmacogenetics and cancer

C Rodriguez-Antona and M Ingelman-Sundberg

Oncogene 25: 1679-1691; doi:10.1038/sj.onc.1209377

Abstract | Full Text | PDF